Table 1 Drug concentrations in fluids and tissues

From: SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity

Analyte

Rectal tissues (fmol/mg or ng/mg)*

Lymph nodes (fmol/106 cells)**

CSF (ng/mL)

Plasma (ng/mL)

TFV

0.64 (0.18–0.87)

n.d.

BLQ

n.d.

TFV-DP

14.6 (5.3–28)*

367 (142–620)

n.d.

n.d.

FTC

1.48 (0.22–2.16)

n.d.

2.36 (BLQ-2.65)

n.d.

FTC-TP

BLQ (BLQ-17)

260 (BLQ-383)

n.d.

n.d.

CAB

0.60 (0.25–2.65)

n.d.

5.95 (4.77–7.43)

835 (480–1050)

RPV

0.45 (0.12–1.1)

n.d.

4.06 (2.93–4.52)

151 (143–153)

  1. Data are expressed as median (range). Extracellular TFV, FTC, CAB, and RPV concentrations were measured in rectal tissues collected after 1 to 3 months of ART. Intracellular TFV-DP and FTC-TP in rectal tissues and lymph nodes were measured in biopsies collected during the study or an earlier 1-month oral FTC/TAF pharmacokinetic study performed in the same macaques46. CSF was collected after ~ 6 months of treatment and 4 weeks after the previous CAB LA/RPV LA injection; data from matched plasma samples are also shown. Source data are provided as a Source Data file.
  2. *fmols/mg of tissue (intracellular TFV-DP and FTC-TP) or ng/mg of tissue (TFV, FTC, CAB and RPV).
  3. **fmols/106 lymph node mononuclear cells.
  4. TFV tenofovir, TFV-DP tenofovir diphosphate, FTC emtricitabine, FTC-TP emtricitabine triphosphate, CAB cabotegravir, RPV rilpivirine, CSF cerebrospinal fluid, n.d., not done, BLQ: below the limit of quantification.
Back to article page